What question did this study set out to answer?

To investigate the molecular mechanisms through which dexrazoxane prevents doxorubicin-induced cardiotoxicity and cardiomyocyte apoptosis.

January 1, 2020BioMed Research InternationalOpen Access

Dexrazoxane Protects Cardiomyocyte from Doxorubicin‐Induced Apoptosis by Modulating miR‐17‐5p

View Full Paper

Ask AI

Bookmark

Why the study?

Dexrazoxane is FDA-approved for preventing doxorubicin-induced cardiotoxicity, but its molecular mechanism is incompletely understood.

Does dexrazoxane prevent doxorubicin-induced cardiomyocyte apoptosis by modulating miR-17-5p in preclinical models?

Population

Male C57BL/6J mice and cardiomyocytes

Comparison

Control vs DOX vs DOX plus dexrazoxane vs dexrazoxane

Design

Randomized preclinical animal and in vitro laboratory study

Authors

XYXiaoxue YuHebei Medical University YRYang RuanFujian Medical University TSTao ShenNanjing Tech University

Discussion

Member takes

Implication

Supports miR-17-5p/PTEN exploration in cardiotoxicity; leaves open clinical translation from animal data.

Key Points

To investigate the molecular mechanisms through which dexrazoxane prevents doxorubicin-induced cardiotoxicity and cardiomyocyte apoptosis.
Male C57BL/6J mice were randomly distributed into control, doxorubicin (DOX), DOX plus dexrazoxane (DOX+DEX), and dexrazoxane (DEX) groups, with cardiac structure and function assessed by echocardiography and histology.
Cultured cardiomyocytes treated with DOX with or without DEX were evaluated using DNA laddering, qRT-PCR, Western blot, and transfection with miR-17-5p mimics or inhibitors.
Dexrazoxane significantly attenuated doxorubicin-induced cardiac injury and reduced cardiomyocyte apoptosis both in vivo and in vitro.
Dexrazoxane upregulated miR-17-5p expression, which directly attenuated phosphatase and tensin homolog (PTEN) expression in cardiomyocytes exposed to doxorubicin.

Structured PICO

Does dexrazoxane prevent doxorubicin-induced cardiomyocyte apoptosis by modulating miR-17-5p in preclinical models?

Population

Male C57BL/6J mice and in vitro cardiomyocytes

Intervention

Dexrazoxane

Comparator

Control, doxorubicin alone, and dexrazoxane alone

Outcome

Heart function and structure, cardiomyocyte apoptosis, and molecular pathway expression (miR-17-5p and PTEN)surrogate

Dexrazoxane exerts its cardioprotective effects against doxorubicin-induced cardiotoxicity at least in part by regulating the miR-17-5p/PTEN cascade to reduce apoptosis.

Cite This Study

Yu et al. (2020) studied this question.

synapsesocial.com/papers/69d57641c23ff40c2825de23 https://doi.org/10.1155/2020/5107193

View Full Paper

Ask AI

Bookmark

Dexrazoxane Protects Cardiomyocyte from Doxorubicin‐Induced Apoptosis by Modulating miR‐17‐5p

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Dexrazoxane Protects Cardiomyocyte from Doxorubicin‐Induced Apoptosis by Modulating miR‐17‐5p

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider